Navigation Links
OLIGOMERIX Awarded NIH Grant to Develop Novel Biomarkers for Alzheimer's Disease
Date:2/25/2009

NEW YORK, Feb. 25 /PRNewswire/ -- OLIGOMERIX, Inc. today announced the receipt of a Small Business Innovation Research (SBIR) Phase I grant for $323,000 from the National Institute on Aging of the National Institutes of Health (NIH). The focus of the program is to develop novel biomarker assays for Alzheimer's disease (AD). Tau oligomers in complex with beta-amyloid or apolipoprotein E (apoE) proteins will be monitored in cerebrospinal fluid (CSF) and plasma from AD patients. The work will be done in collaboration with Drs. Lawrence S. Honig and Richard Mayeux at the Taub Institute for Research on Alzheimer's disease and the Aging Brain at Columbia University Medical Center (CUMC).

There is a critical unmet need for novel biomarkers for AD, both with respect to differential diagnosis of AD at first evaluation, and for monitoring disease progression. Presently, definitive diagnosis of AD can only be accomplished after death, through brain autopsy. There are no validated biomarkers from patient samples such as CSF or plasma that predict progression or regression of AD. OLIGOMERIX plans to evaluate novel AD biomarkers based on the paradigm of protein-protein interactions. This strategy may enable more specific diagnosis and disease monitoring, for better patient management.

"Our focus is to develop assays that can be used for drug discovery for AD," stated James Moe, Ph.D., MBA, President and CEO of OLIGOMERIX "Any validated assays developed under this program for disease staging or definitive diagnosis of AD will be potential out-licensing opportunities for the company."

ABOUT OLIGOMERIX

OLIGOMERIX, Inc. is a biopharmaceutical company founded in 2006 located at Audubon Biomedical Science and Technology Park, CUMC. The Company is developing a drug discovery platform that includes biomarker assays for discovering small molecule inhibitors of tau oligomer formation that are novel AD targets.

For more information visit www.oligomerix.com.

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated. Risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding, contract research, and services.

    CONTACTS:
    OLIGOMERIX, Inc.
    James Moe, President and CEO
    212-568-0365 Ext. 18
    jmoe@oligomerix.com

    Richard Lewis Communications, Inc.
    212-827-0020
    Cecelia Heer, Investors
    cheer@rlcinc.com
    Gregory Tiberend, Media
    gtiberend@rlcinc.com


'/>"/>
SOURCE OLIGOMERIX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peter Zoller and Ignacio Cirac, awarded by the BBVA Foundation
2. Origin BioMed Awarded Red Herring Top 100 Global Company
3. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
4. Eurotech Catalyst Module Awarded to Allen Organ Company From Arrow Electronics
5. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
6. Probiotic Delivery Technology Awarded Third International Patent
7. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
8. China Medicine Corporation Awarded GSP Certification
9. Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission
10. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
11. Yale professor T.P. Ma awarded the Connecticut Medal of Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... DIEGO and SAN FRANCISCO ... a privately-held regenerative medicine company, and Beyond Type 1, ... with type 1 diabetes, today announced a grant from ... a functional cure for type 1 and other insulin-requiring ... ViaCyte has been developing innovative stem cell-derived cell replacement ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... acquired Kendall Research Systems, LLC (KRS) clinical development program. KRS is ... interface technology for research and clinical applications. The terms of the transaction were ...
(Date:2/22/2017)... , Feb. 22, 2017 Scientists propose in ... and organ damage in Gaucher and maybe other lysosomal ... and lower costs than current therapies. An ... Medical Center , which also included investigators from the ... report their data Feb. 22. The study was conducted ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... and scientists from around the world, is pleased to announce the 2nd annual ... 23, 2017. This premier, online-only conference focused on the development and advancements in ...
Breaking Biology Technology:
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 /PRNewswire/ ... point. Driven largely by the confluence of organizations, ... users, distaste for knowledge-based systems (password and challenge ... consumer, industrial, and government systems. The market is ... been a demarcation between consumer and enterprise uses ...
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Biology News(10 mins):